About 10X Genomics
10X Genomics is a company based in Pleasanton (United States) founded in 2012. 10X Genomics has raised $199.9 million across 7 funding rounds from investors including Fidelity Investments, SVB and SoftBank Group. The company has 1,310 employees as of December 31, 2024. 10X Genomics has completed 7 acquisitions, including CARTANA, Epinomics and Proteintech Group. 10X Genomics operates in a competitive market with competitors including Mission Bio, Element Biosciences, Cellares, LUMICKS and Xcell Biosciences, among others.
- Headquarter Pleasanton, United States
- Employees 1310 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 10X Genomics, Inc.
-
Annual Revenue
$610.78 M (USD)-1.28as on Dec 31, 2024
-
Net Profit
-$182.63 M (USD)28.41as on Dec 31, 2024
-
EBITDA
-$148.49 M (USD)6.17as on Dec 31, 2024
-
Total Equity Funding
$199.9 M (USD)
in 7 rounds
-
Latest Funding Round
$85 M (USD), Series D
Jan 07, 2019
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
1310
as on Dec 31, 2024
-
Investments & Acquisitions
CARTANA
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 10X Genomics
10X Genomics is a publicly listed company on the NASDAQ with ticker symbol TXG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of 10X Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of 10X Genomics
10X Genomics has successfully raised a total of $199.9M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $85 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 10X Genomics
10X Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, SVB and SoftBank Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward US-based companies.
|
Locked | Locked | Locked | |
|
Venture capital is invested in multiple sectors by Paladin Capital.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for 10X Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 10X Genomics
10X Genomics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include CARTANA, Epinomics and Proteintech Group.
Investment portfolio details for 10X Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Scale Biosciences is a company developing single-cell library preparation kits for genomic, epigenomic, and transcriptomic analysis.
|
Locked | Locked | 2020 | Locked | |
|
Antigens, peptides, and tetramers for research are supplied online.
|
Locked | Locked | 2018 | Locked | |
|
Provider of gene expression mapping technology in brain tissue
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for 10X Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - 10X Genomics
Detailed financials for 10X Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
10X Genomics Comparisons
Peer comparison for 10X Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 10X Genomics
10X Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mission Bio, Element Biosciences, Cellares, LUMICKS and Xcell Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Benchtop DNA sequencers are developed for research and diagnostic uses.
|
|
| Locked | Locked | Locked |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| Locked | Locked | Locked |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| Locked | Locked | Locked |
Cell culture analysis devices for cancer research are developed.
|
Detailed competitors of 10X Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 10X Genomics
Complete news archive for 10X Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 10X Genomics
10X Genomics was founded in 2012.
10X Genomics is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
10X Genomics is a funded company, having raised a total of $199.9M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at 10X Genomics is 1,310.
Annual revenue of 10X Genomics is $610.78M as on Dec 31, 2024.
10X Genomics was founded in 2012 and is headquartered in Pleasanton, United States. Instrument systems for genomic research are developed, including the Chromium platform with reagents and consumables for preparing sequencing libraries compatible with Illumina systems. Software for sequence analysis is provided, along with services such as whole-genome sequencing and exome sequencing. Operations focus on partitioning cells or DNA fragments via GemCode technology to enable barcoded libraries.
10X Genomics's top competitors include Mission Bio, Element Biosciences and Cellares.
Yes, 10X Genomics is publicly traded on NASDAQ under the ticker symbol TXG.
10X Genomics has made 7 acquisitions, including CARTANA, Epinomics, and Proteintech Group.
10X Genomics has 10 investors. Key investors include Fidelity Investments, SVB, SoftBank Group, Wells Fargo, and European Union.
The ticker symbol of 10X Genomics is TXG on NASDAQ.